Organon Issues 2023 ESG Report, Highlighting Strides in Women’s Health Equity and Environmental Stewardship
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today released its 2023 Environmental, Social and Governance (ESG) Report.
Central to its mission to advance the health of women, the company focuses its ESG efforts on three core areas: Advancing Her Equity, innovating to support and expand access to women’s health solutions and advancing gender equity inside and outside Organon; Protecting Her Planet, working to implement environmentally responsible practices and long-term sustainability initiatives; and Building Her Trust, continuing to uphold the highest levels of ethics and integrity among business operations.
“Our achievements in innovation, access and environmental stewardship reflect our unwavering dedication to creating a better and healthier every day for every woman,” said Kevin Ali, Organon CEO. “We are proud of the strides we have made toward our ESG goals. We remain committed to advancing women’s health, ensuring our actions today create a healthier and more equitable future for patients everywhere."
Highlights of Organon's progress and achievements across ESG core focus areas include:
- Advancing Her Equity
- Accelerated progress in innovating for women's health: Successfully completed nine transactions, including two in 2023: A strategic investment in Claria Medical, a privately held company developing an investigational medical device being studied for use during minimally invasive laparoscopic procedures; and an agreement with Eli Lilly in Europe aimed at building on strong commercial expertise in central nervous system disorders. Organon continues to identify, evaluate and invest in partnerships to unlock options that support and address women’s unmet needs.
- Helped prevent unintended pregnancies: Surpassed the halfway point of the company’s goal to help prevent an estimated 120 million unintended pregnancies by 2030 through the Her Promise Access Initiative. To date, Organon helped prevent approximately 65 million unintended pregnancies and provided more than 54 million women and girls in low- and middle-income countries affordable access to contraceptive options.
- Advanced gender equity: Female representation in roles at director-level and above increased to 47%, up from 43% three years ago, making progress towards the company’s diversity, equity, inclusion and belonging (DEI&B) goals. In addition, Organon achieved 100% balance in pay equity, validated through pay equity studies conducted by external economic and legal experts in nine of our largest markets [1] for similarly situated female and male employees in equivalent positions [2].
- Protecting Her Planet
- Reduced Scope 1 and 2: Reduced Scope 1 and Scope 2 GHG emissions [3] by 6.6% against a 2020 baseline. To continue these emissions reductions, Organon is entering into a virtual purchase power agreement with Schneider Electric to secure renewable electricity for manufacturing sites in Oss, Netherlands, and Heist, Belgium, for the next 10 years, starting in December 2025.
- Exceeded recycling goal: Reused, recycled or otherwise used beneficially [4] 93% of operational waste from Organon’s six manufacturing sites, surpassing the 2025 goal of 80%.
- Building Her Trust
- Maintained gender equity in governance: Maintained a Board composition of nearly 70% women since Organon’s founding in 2021, with two-thirds (66%) of its standing Board committees chaired by women.
“Since our launch as an independent company three years ago, we have made significant progress against our ESG commitments and vision to advance the complete health of women at all stages of her life journey,” said Carrie Cox, Chairman, Organon’s Board of Directors. “We believe by advancing the health of women, we advance the health of society. I’m energized by the progress we’ve made and what’s to come as we continue to innovate to improve the lives of women around the world.”
To learn more about Organon’s ESG strategy and progress, visit Organon’s ESG microsite at https://www.organon.com/esg/.
About Organon
Organon is an independent global healthcare company with a strategy to help improve the health of women throughout their lives. Organon’s diverse portfolio offers more than 60 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon’s current products, the company invests in innovative solutions and research to drive future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical partners and innovators looking to commercialize their products by leveraging its scale and agile presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.
For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.
Cautionary Note Regarding Forward-Looking Statements
Some statements and disclosures in this press release are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about expectations regarding the drug as a treatment for dysmenorrhea, as well trials and regulatory approvals for the drug. Forward-looking statements may be identified by words such as “foresees” “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon’s filings with the Securities and Exchange Commission (“SEC”), including Organon’s most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC’s Internet site (www.sec.gov).
[1] Australia, Brazil, Canada, Portugal, Spain, Switzerland, the United Kingdom and the United States.
[2] Adjusted to account for legitimate labor economic factors.
[3] Including biogenic emissions.
[4] Otherwise used beneficially includes composting and incinerated with heat recovery.
Organon Media Relations
media@organon.com
